Comparative Pharmacology
Head-to-head clinical analysis: CAM METRAZINE versus DIMETHYL SULFOXIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAM METRAZINE versus DIMETHYL SULFOXIDE.
CAM-METRAZINE vs DIMETHYL SULFOXIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CAM-METRAZINE (metformin and rosiglitazone combination) improves glycemic control by decreasing hepatic glucose production (metformin, AMPK activation) and increasing insulin sensitivity in peripheral tissues (rosiglitazone, PPARγ agonist).
Dimethyl sulfoxide (DMSO) is a polar aprotic solvent that penetrates biological membranes, scavenges hydroxyl radicals, and stabilizes lysosomal membranes. It has anti-inflammatory, analgesic, and cryoprotective properties. It enhances cutaneous absorption of other drugs and induces histamine release from mast cells, causing vasodilation and urticaria.
Initial dose: 30 mg orally once daily; may increase to 60 mg orally once daily after 2 weeks, then to 90 mg orally once daily after another 2 weeks. Maximum dose: 90 mg/day.
50% solution topically applied every 6 hours; intravenous: 0.5-1 g/kg as a 10-20% solution over 30-60 minutes every 6 hours for 3-5 doses
None Documented
None Documented
Clinical Note
moderateDimethyl sulfoxide + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dimethyl sulfoxide."
Clinical Note
moderateDimethyl sulfoxide + Atorvastatin
"The risk or severity of adverse effects can be increased when Dimethyl sulfoxide is combined with Atorvastatin."
Clinical Note
moderateDimethyl sulfoxide + Dexrazoxane
"The therapeutic efficacy of Dexrazoxane can be decreased when used in combination with Dimethyl sulfoxide."
Clinical Note
moderateTerminal elimination half-life is 6-8 hours in adults with normal renal function; prolonged to 12-20 hours in moderate renal impairment (CrCl <50 mL/min), requiring dose adjustment.
Terminal half-life: 11-14 hours for DMSO; DMSO2 half-life 60-70 hours, accumulates with repeated dosing. Clinical context: renal impairment prolongs half-life.
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; minor biliary/fecal (5-10%).
Renal: 30-50% unchanged; hepatic metabolism to dimethyl sulfone (DMSO2) and dimethyl sulfide (DMS); DMSO2 excreted renally, DMS exhaled; fecal elimination <5%.
Category C
Category C
Topical Analgesic
Topical Analgesic
Metoprolol + Dimethyl sulfoxide
"The serum concentration of Dimethyl sulfoxide can be increased when it is combined with Metoprolol."